Director, CEO buying at ESSA Pharma (EPI)

Director, CEO buying at ESSA Pharma (V:EPI)

Franklin Milan Berger, a Director, acquired 3,125,000 Common Shares on a direct ownership basis at a price of US$0.20 through a private transaction on January 9th, 2018. This represents a $778,375 investment into the company's shares and an account share holdings change of greater than 100%.

David Parkinson, CEO and Director, acquired 250,000 Common Shares on a direct ownership basis at a price of US$0.20 through a private transaction on January 9th, 2018. This represents a $62,270 investment into the company's shares and an account share holdings change of greater than 100%.

ESSA Pharma is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR). The Company's product candidate, EPI-506 is a selective, oral small molecule pro-drug that blocks the N-terminal domain of the AR. EPI-506 is a pro-drug of EPI-002, a stereoisomer of the Company's discovery compound, EPI-001. The Company is conducting a Phase I/II clinical study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and efficacy of EPI-506 in patients with metastatic CRPC. It is focused on developing EPI-506 as its clinical-development product candidate. ESSA Pharmaceuticals Corp. is the Company's subsidiary. The Company has not generated any revenues.